The COVID-19 pandemic has prompted regulators and the industry to consider how best to prepare for future emergencies. In June 2023, the European Commission finalized deals with various European pharmaceutical companies to reserve manufacturing capacity for up to 325 million vaccine doses annually in case of a future public health emergency.
Thomas Zimmer, Vice President of European Operations at ISPE, weighs in on how the industry is taking steps to quickly increase production if required, noting monitoring and communication will be key to any future responses. He also points to additional considerations for future strategies.
The Medicine Maker covers pressing topics, trends, and technologies covering the entire spectrum of drug development. The publication highlights industry success stories and insights from professionals who develop and manufacture small molecules, biologics, and advanced therapies.